Zenith Drugs Ltd (ZENITHDRUG) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 0 | NSE: ZENITHDRUG | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

Zenith Drugs Ltd (ZENITHDRUG) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 0 | NSE: ZENITHDRUG | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Zenith Drugs

Based on:

M-Cap below 100cr DeciZen not available

Zenith Drugs stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
13.08
Market Cap:
93.6 Cr.
52-wk low:
0
52-wk high:
0

Is Zenith Drugs Ltd an attractive stock to invest in?

1. Is Zenith Drugs Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Zenith Drugs Ltd is a below average quality company.

2. Is Zenith Drugs Ltd undervalued or overvalued?

The key valuation ratios of Zenith Drugs Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

3. Is Zenith Drugs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Zenith Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Zenith Drugs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Zenith Drugs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 24.3%23.9%25.1%25.2%13%-
Value Creation
Index
0.70.70.80.8-0.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 73.491.7115132133133
Sales YoY Gr.-24.9%24.9%14.9%1.3%-
Adj EPS 2.62.74.56.24.34.2
YoY Gr.-4.7%69%36.9%-31.3%-
BVPS (₹) 810.714.836.340.540.5
Adj Net
Profit
3.13.25.410.67.37
Cash Flow from Ops. -0.94.9-4.3-15.8-5.5-
Debt/CF from Ops. -17.53.4-6-1.5-8.9-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANA13.3%1.3%
Adj EPS NANA16.7%-31.3%
BVPSNANA55.7%11.5%
Share Price - - - -38.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
31.828.635.526.611.110.3
Op. Profit
Mgn %
9.87.68.812.610.4NAN
Net Profit
Mgn %
4.23.54.88.15.55.4
Debt to
Equity
1.61.31.40.40.7-
Working Cap
Days
01591982392740
Cash Conv.
Cycle
01614371030

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 13.30%

Net Profit is growing at healthy rate in last 3 years 16.71%

Debt to equity has declined versus last 3 years average to 0.70

Return on Equity has declined versus last 3 years average to 10.30%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Zenith Drugs Ltd.

Standalone Consolidated
TTM EPS (₹) 4.2 5.6
TTM Sales (₹ Cr.) 133 132
BVPS (₹.) 40.5 0
Reserves (₹ Cr.) 52 45
P/BV 1.35 0.00
PE 13.08 9.76
From the Market
52 Week Low / High (₹) 0.00 / 0.00
All Time Low / High (₹) - / -
Market Cap (₹ Cr.) 93.6
Equity (₹ Cr.) 17.2
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Zenith Drugs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Zenith Drugs - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Zenith Drugs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Sales73.4091.66114.52131.62133.32
Operating Expenses 66.2084.73105.31115.02119.49
Manufacturing Costs1.542.7329.3437.1334.55
Material Costs52.4172.5156.4256.7063.46
Employee Cost 2.412.984.095.346.76
Other Costs 9.846.5115.4615.8414.72
Operating Profit 7.206.929.2116.6013.83
Operating Profit Margin (%) 9.8%7.6%8.0%12.6%10.4%
Other Income 0.110.951.242.552.61
Interest 1.492.142.4933.96
Depreciation 1.221.341.301.302.97
Exceptional Items 000-1.56-0.25
Profit Before Tax 4.604.406.6613.299.26
Tax 1.531.191.783.762.10
Profit After Tax 3.073.214.889.547.16
PAT Margin (%) 4.2%3.5%4.3%7.2%5.4%
Adjusted EPS (₹)2.62.74.15.64.2
Dividend Payout Ratio (%)0%0%0%9%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 9.6412.8517.7362.2269.38
Share Capital 0.400.400.4017.1517.15
Reserves 9.2412.4517.3345.0752.23
Minority Interest00000
Debt15.4816.7923.4621.8642.99
Long Term Debt7.287.587.677.8512.80
Short Term Debt8.219.2015.7914.0130.19
Trade Payables20.2634.4050.8742.6340.18
Others Liabilities 1.162.155.167.408.92
Total Liabilities 46.5466.1897.22134.11161.47

Fixed Assets

Gross Block14.2316.8018.4819.9052.18
Accumulated Depreciation5.016.357.668.9611.92
Net Fixed Assets 9.2110.4510.8210.9440.26
CWIP 0003.913.10
Investments 00.030.030.030
Inventories6.8312.1323.6725.7639.61
Trade Receivables23.3932.0749.3167.3960.58
Cash Equivalents 1.852.890.208.740.26
Others Assets 5.268.6213.1917.3417.65
Total Assets 46.5466.1897.22134.11161.47

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -0.894.91-4.27-15.84-5.47
PBT 4.604.406.6613.299.51
Adjustment 2.533.473.634.306.38
Changes in Working Capital -6.67-1.72-12.73-26.44-15.6
Tax Paid -1.36-1.24-1.83-3.99-2.05
Cash Flow From Investing Activity -1.43-2.61-2.05-5.33-31.41
Capex -1.43-2.61-1.67-1.42-32.28
Net Investments 00000.07
Others 00-0.38-3.910.81
Cash Flow From Financing Activity 2.88-0.836.3029.7228.39
Net Proceeds from Shares 00034.950
Net Proceeds from Borrowing 000.090.184.94
Interest Paid -1.32-2.14-2.3300
Dividend Paid 00000
Others 4.201.308.54-5.4223.45
Net Cash Flow 0.571.47-0.018.55-8.48

Finance Ratio

PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)31.8228.5731.9223.8610.88
ROCE (%)24.2523.8725.1225.212.96
Asset Turnover Ratio1.741.81.571.31.03
PAT to CFO Conversion(x)-0.291.53-0.88-1.66-0.76
Working Capital Days
Receivable Days105100116142154
Inventory Days3134516079
Payable Days141138276301238

Zenith Drugs Ltd Stock News

Zenith Drugs Ltd FAQs

The current trading price of Zenith Drugs on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Zenith Drugs stood at ₹93.63.
The latest P/E ratio of Zenith Drugs as of 31-Dec-1969 is 13.08.
The latest P/B ratio of Zenith Drugs as of 31-Dec-1969 is 1.35.
The 52-week high of Zenith Drugs is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Zenith Drugs is ₹133.3 ( Cr.) .

About Zenith Drugs Ltd

Zenith Drugs Limited was originally incorporated on November 15, 2000 as a Private Limited Company in the name of ‘Zenith Drugs Private Limited’ under the provisions of the Companies Act, 1956 with the Registrar of Companies, Madhya Pradesh, Gwalior. Subsequently pursuant to a Special Resolution of its Shareholders passed in the Extra-Ordinary General Meeting held on September 05, 2023, the Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of the Company was changed to ‘Zenith Drugs Limited’ and a Fresh Certificate of Incorporation consequent to Conversion was issued on September 13, 2023 by the Registrar of Companies, Gwalior.

The company is a pharmaceutical manufacturing and trading company based out from Indore. It has a manufacturing unit, dedicated to ensuring the highest quality standards when it comes to manufacturing of medicines. It is specialized in manufacturing high quality and affordable Medicines to support its patients in need. The company is also into Generic Medicines and Generic Medicines are cost effective. Since its inception, the company has focused on building a strong foundation and laying the groundwork for its future growth and success. With dedication and strategic planning, it managed to establish a reputable presence in the pharmaceutical industry. The company was incorporated with the objective of the better service deliverance in field of medicine and be better premium pharmaceutical companies in India and abroad for cost effective human medicine. The company always emphasis on core strength and policies that focus on technology and great deliverance. With a passion to set high standards of services, the company has always taken all measures to scale up as and when required only to deliver the better. The company works diligently and has a wide range of products to cater to every need and to reach the client sensitivity and centricity.

The company has Certificate of Good Manufacturing Practices issued by Office of the Controller, Food and Drugs Administration, Madhya Pradesh, Idgah Hills, Bhopal, Madhya Pradesh. The quality standards of the company are based on adherence to Good Manufacturing Practices (GMP) guidelines, regulatory requirements and internal quality control processes. The Company is constantly required to adhere to the same. These measures are implemented to ensure the highest level of quality in its manufacturing operations. Building upon its commitment to excellence, it has completed two expansions within the same facility to accommodate the growing demand for its products. These expansions have allowed the company to scale its operations, increase production capacity, and introduce new formulations. Through these strategic investments and expansions, the company strives to continuously improve its manufacturing infrastructure, enhance product quality, and meet the evolving needs of healthcare professionals and patients.

Business area of the company

The company is mainly engaged in the business of manufacturing and Trading of Medicines.

Products of the company

Liquid oral

  • Iron & Folic acid syrup IP
  • Hungrykop syrup
  • BIozen multivitamin syrup
  • Rexkop DX syrup
  • Zoomol plus syrup

Ointment / Cream

  • POVIZ ointment
  • Clobetol GM cream
  • Painfree gel
  • Poviz M ointment
  • Candizen cream

Liquid external section

  • Poviz solutin (Lotion)
  • Bioscaby lotion
  • Permethirn lotion
  • Gamma Benzene Hexachloride 1% lotion
  • Scabikop lotion

Capsule section

  • Pyvoxee spas plus capsule
  • BIO-Omi capsule
  • Lopagen capsule
  • Cold-time capsule
  • Rabijen DSR capsule

ORS section

  • Zenith ORS
  • Koplyte ORS
  • Oral rehydration salts IP 20.50 gm
  • Oral rehydration salts BP 27.90 gm

History and milestones

  • 2000: Incorporation of the Company.
  • 2001: Started as a manufacturing house for oral and external formulations.
  • 2004: Shifted to a Schedule M GMP compliant unit.
  • 2004: Started the production of two lines which are liquid orals and ointments.
  • 2007: Started manufacturing ORS Powder.
  • 2016: Received WHO GMP certification.
  • 2019: Turnover crossed Rs 50 crore.
  • 2020: Turnover crossed Rs 75 crore.
  • 2021: Certificate of Quality Management System ISO 9001:2015 issued by Global Grading Certification.
  • 2021: Certificate of compliance with good manufacturing practices issued by Liberia Medicines and Health Products Regulatory Authority.
  • 2021: The Company received subsidy under Madhya Pradesh MSME Yojna i.e. MSME Promotion Scheme, 2019 as Industrial Development Grant upto 40% of the capital invested in machinery i.e. grant of Rs 170.04 lakh.
  • 2022: The Company was recognized as among top 10 MSME Pharmaceutical Manufacturers in Indore in Industry Outlook Magazine Edition.
  • 2023: Turnover crossed Rs 100 crore.
  • 2023: Collaborated with Mr. Kshatriya Valtaprasad Nandkishore for Carrying out the task of Marketing and Export of the products manufactured by Zenith.
  • 2023: Conversion of the Company from Private Limited Company to Public Limited Company.

You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×